Clinical Trial Update: Study to Evaluate the Safety of ATR-04 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 safety study of ATR-04 by Azitra Inc. has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papulopustular Rosacea

Drugs mentioned

• ATR-04

Snippet

Sponsor: Azitra Inc. | Conditions: Epidermal Growth Factor, Papulopustular Rosacea | Phase 1, Phase 2 | Status: WITHDRAWN